Hikari Power Ltd boosted its holdings in Celgene Co. (NASDAQ:CELG) by 25.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 71,970 shares of the biopharmaceutical company’s stock after purchasing an additional 14,570 shares during the quarter. Celgene comprises approximately 0.9% of Hikari Power Ltd’s investment portfolio, making the stock its 25th largest holding. Hikari Power Ltd’s holdings in Celgene were worth $7,511,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Daiwa SB Investments Ltd. grew its position in Celgene by 15.9% in the 4th quarter. Daiwa SB Investments Ltd. now owns 10,040 shares of the biopharmaceutical company’s stock valued at $1,048,000 after purchasing an additional 1,380 shares during the period. Lederer & Associates Investment Counsel CA boosted its holdings in Celgene by 22.4% during the 4th quarter. Lederer & Associates Investment Counsel CA now owns 17,745 shares of the biopharmaceutical company’s stock worth $1,852,000 after acquiring an additional 3,246 shares during the last quarter. Kistler Tiffany Companies LLC boosted its holdings in Celgene by 14.0% during the 4th quarter. Kistler Tiffany Companies LLC now owns 7,641 shares of the biopharmaceutical company’s stock worth $797,000 after acquiring an additional 937 shares during the last quarter. LGT Capital Partners LTD. boosted its holdings in Celgene by 38.5% during the 4th quarter. LGT Capital Partners LTD. now owns 354,850 shares of the biopharmaceutical company’s stock worth $37,032,000 after acquiring an additional 98,665 shares during the last quarter. Finally, Stock Yards Bank & Trust Co. boosted its holdings in Celgene by 24.6% during the 4th quarter. Stock Yards Bank & Trust Co. now owns 147,819 shares of the biopharmaceutical company’s stock worth $15,427,000 after acquiring an additional 29,140 shares during the last quarter. 78.10% of the stock is owned by institutional investors and hedge funds.

In other Celgene news, insider Mark J. Alles acquired 3,260 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was bought at an average price of $91.90 per share, with a total value of $299,594.00. Following the completion of the acquisition, the insider now owns 178,904 shares of the company’s stock, valued at $16,441,277.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.95% of the stock is currently owned by insiders.

Shares of Celgene Co. (NASDAQ:CELG) opened at $92.51 on Monday. Celgene Co. has a 52-week low of $88.32 and a 52-week high of $147.17. The firm has a market capitalization of $69,583.77, a PE ratio of 13.48, a PEG ratio of 0.66 and a beta of 1.49. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The company had revenue of $3.48 billion during the quarter, compared to analyst estimates of $3.46 billion. During the same quarter in the previous year, the firm earned $1.61 earnings per share. Celgene’s revenue was up 16.9% on a year-over-year basis. sell-side analysts predict that Celgene Co. will post 7.68 EPS for the current year.

A number of equities analysts have issued reports on CELG shares. Sanford C. Bernstein downgraded shares of Celgene from an “outperform” rating to a “market perform” rating and set a $121.00 price objective on the stock. in a report on Wednesday, December 27th. BTIG Research reaffirmed a “hold” rating on shares of Celgene in a report on Sunday, October 22nd. Cantor Fitzgerald reaffirmed a “hold” rating and set a $112.00 price objective on shares of Celgene in a report on Monday, October 30th. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective on the stock in a report on Monday, October 23rd. Finally, Oppenheimer set a $166.00 price objective on shares of Celgene and gave the stock a “buy” rating in a report on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $130.35.

COPYRIGHT VIOLATION WARNING: This report was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://theolympiareport.com/2018/02/12/hikari-power-ltd-boosts-position-in-celgene-co-celg.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.